ProCE Banner Activity

CME

Looking to the Horizon: Emerging Therapies and the Near Future Evolution in Prostate Cancer

Video

Get up to date with this on-demand webcast from a live symposium focused on new and emerging therapies in patients with prostate cancer.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 28, 2023

Expiration: March 27, 2024

Share

Faculty

Neeraj Agarwal

Neeraj Agarwal, MD

Professor of Medicine
Senior Director for Clinical Research Innovation, Huntsman Cancer Institute (HCI)
Presidential Endowed Chair of Cancer Research
Director
, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah (NCI-CCC)

Tanya B. Dorff

Tanya B. Dorff, MD

Associate Professor
Department of Medical Oncology & Therapeutics Research
Section Chief, Genitourinary Cancers
City of Hope
Duarte, California

Rana R. McKay

Rana R. McKay, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
Genitourinary Oncology Team Lead
Moores Cancer Center
La Jolla, California

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

Exelixis, Inc.

Lilly

Pfizer, Inc.

Target Audience

This educational program is intended for medical oncologists, urologists, and other healthcare professionals who treat patients with prostate cancer.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in the integration of novel therapies into the care of patients with prostate cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appraise novel therapeutically actionable molecular targets that hold promise as predictive or prognostic biomarkers for patients with prostate cancer

  • Plan optimal, individualized sequential therapeutic strategies for prostate cancer, considering all available agents, clinical data including novel investigational therapeutics and imaging techniques, and expert recommendations

  • Identify patients with prostate cancer who may be eligible for enrollment on ongoing clinical studies investigating novel regimens

  • Assess recent trial evidence from studies that evaluated novel approaches for prostate cancer in the context of their impact on evolving paradigms in the field

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Neeraj Agarwal, MD, FASCO: advisor: Avea, Exelixis, Foundation Medicine, Gilead Services, Lilly, Merck.

Tanya B. Dorff, MD: consultant/advisor/speaker: Astellas, AstraZeneca, Bayer, Exelixis, Janssen, Sanofi, SeaGen.

Rana R. McKay, MD: consultant/advisor/speaker: AstraZeneca, Aveo, Bayer, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Johnson & Johnson, Lilly, Merck, Myovant, Novartis, Pfizer, Sanofi, SeaGen, Sorrento Therapeutics, Telix, Tempus; researcher: AstraZeneca, Bayer, Tempus.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from March 28, 2023, through March 27, 2024:

  1. Create an account or Login at https://clinicaloptions.com
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

Joint Accreditation

 

 

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Continuing Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation
CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.